IDEAYA Biosciences, founded in South San Francisco, California, is a clinical-stage precision medicine oncology company. The company's core mission is to improve lives through transformative precision medicines. IDEAYA focuses on developing targeted therapeutics for cancer treatment, specifically for patient populations selected using molecular diagnostics. Their primary area of expertise is synthetic lethality, an emerging class of precision medicine targets.
Notable affiliated people include prominent scientists and industry leaders who have significantly contributed to the field of oncology. IDEAYA has garnered substantial investment from leading venture capital firms and strategic partners in the healthcare sector. Key achievements include advancing several first-in-class and best-in-class therapeutics into clinical trials, demonstrating significant potential in cancer treatment. The company's impact is marked by its innovative approach to precision medicine, aiming to provide more effective and personalized cancer therapies.